The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesVerena Hoffmann, Rüdiger Hehlmann, Andrija Bogdanović et al.|Leukemia|2015Cited by 255
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Corrado Tarella, Federica De Marco et al.|Blood|2008Cited by 253
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalAntonio Palumbo, Michèle Cavo, Sara Bringhen et al.|Journal of Clinical Oncology|2014Cited by 210
Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma NetworkEva Hoster, Michael Unterhalt, Wolfgang Hiddemann et al.|Journal of Clinical Oncology|2014Cited by 164
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classificationLaura Pasqualucci, Brunangelo Falini, Arcangelo Liso et al.|Blood|2006Cited by 103